GU Cancer

Survival benefits with androgen receptor signalling inhibitors seen in prostate cancer

Treatment intensification with currently available androgen receptor signalling inhibitors improves survival in men with hormone/castration-sensitive prostate cancer (CSPC), according to results presented at the ESMO Congress 2021. The PEACE-1 study showed that addition of abiraterone acetate plus prednisone (AAP) produced clear survival improvements in patients with metastatic prostate cancer, the conference heard. A second trial, the STAMPEDE ...

Already a member?

Login to keep reading.

© 2022 the limbic